These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 20224930)

  • 1. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes.
    Boye KS; Matza LS; Walter KN; Van Brunt K; Palsgrove AC; Tynan A
    Eur J Health Econ; 2011 Jun; 12(3):219-30. PubMed ID: 20224930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilities and disutilities for type 2 diabetes treatment-related attributes.
    Matza LS; Boye KS; Yurgin N; Brewster-Jordan J; Mannix S; Shorr JM; Barber BL
    Qual Life Res; 2007 Sep; 16(7):1251-65. PubMed ID: 17638121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes.
    Matza LS; Boye KS; Stewart KD; Davies EW; Paczkowski R
    BMC Health Serv Res; 2017 Nov; 17(1):774. PubMed ID: 29178918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health state utilities associated with attributes of treatments for hepatitis C.
    Matza LS; Sapra SJ; Dillon JF; Kalsekar A; Davies EW; Devine MK; Jordan JB; Landrian AS; Feeny DH
    Eur J Health Econ; 2015 Dec; 16(9):1005-18. PubMed ID: 25481796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valuing injection frequency and other attributes of type 2 diabetes treatments in Australia: a discrete choice experiment.
    Fifer S; Rose J; Hamrosi KK; Swain D
    BMC Health Serv Res; 2018 Aug; 18(1):675. PubMed ID: 30165844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilities for Type 2 Diabetes Treatment-Related Attributes in a South Korean and Taiwanese Population.
    Rajan N; Boye KS; Gibbs M; Lee YJ; Davey P; Ball M; Babineaux SM
    Value Health Reg Issues; 2016 May; 9():67-71. PubMed ID: 27881263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preferences of patients with diabetes mellitus for inhaled versus injectable insulin regimens.
    Chancellor J; Aballéa S; Lawrence A; Sheldon R; Cure S; Plun-Favreau J; Marchant N
    Pharmacoeconomics; 2008; 26(3):217-34. PubMed ID: 18282016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Health State Utility Measures in Patients With Head and Neck Cancer.
    Noel CW; Lee DJ; Kong Q; Xu W; Simpson C; Brown D; Gilbert RW; Gullane PJ; Irish JC; Huang SH; O'Sullivan B; Goldstein DP; de Almeida JR
    JAMA Otolaryngol Head Neck Surg; 2015 Aug; 141(8):696-703. PubMed ID: 26204439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes.
    Matza LS; Cutts KN; Stewart KD; Norrbacka K; García-Pérez LE; Boye KS
    Qual Life Res; 2021 Jul; 30(7):2033-2043. PubMed ID: 33886044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obese versus non-obese patients with type 2 diabetes: patient-reported outcomes and utility of weight change.
    Matza LS; Yurgin N; Boye KS; Malley K; Shorr JM
    Curr Med Res Opin; 2007 Sep; 23(9):2051-62. PubMed ID: 17651535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discrete Choice Experiment Attribute Selection Using a Multinational Interview Study: Treatment Features Important to Patients with Type 2 Diabetes Mellitus.
    Rydén A; Chen S; Flood E; Romero B; Grandy S
    Patient; 2017 Aug; 10(4):475-487. PubMed ID: 28315192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilities for treatment-related adverse events in type 2 diabetes.
    Shingler S; Fordham B; Evans M; Schroeder M; Thompson G; Dewilde S; Lloyd AJ
    J Med Econ; 2015 Jan; 18(1):45-55. PubMed ID: 25266815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flexible insulin dosing improves health-related quality-of-life (HRQoL): a time trade-off survey.
    Evans M; Jensen HH; Bøgelund M; Gundgaard J; Chubb B; Khunti K
    J Med Econ; 2013 Nov; 16(11):1357-65. PubMed ID: 24111563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient preferences in Italy: health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes.
    Matza LS; Boye KS; Jordan JB; Norrbacka K; Gentilella R; Tiebout AR; Browne C; Orsini Federici M; Biricolti G; Stewart KD
    Patient Prefer Adherence; 2018; 12():971-979. PubMed ID: 29922043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The utility score of epilepsy with partial seizure measured by TTO, VAS, and EQ-5D in the general Korean population.
    Kang HJ; Kang E; Jo MW; Park EJ; Yoon S; Lee EK
    Epilepsy Res; 2014 Jul; 108(5):963-71. PubMed ID: 24679945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimation of a valuation function for a diabetes mellitus-specific preference-based measure of health: the Diabetes Utility Index.
    Sundaram M; Smith MJ; Revicki DA; Miller LA; Madhavan S; Hobbs G
    Pharmacoeconomics; 2010; 28(3):201-16. PubMed ID: 20151725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A valuation of infusion therapy to preserve islet function in type 1 diabetes.
    Lloyd A; Swinburn P; Boye KS; Curtis B; Sarpong E; Goldsmith K; Bode B; Aronoff S
    Value Health; 2010 Aug; 13(5):636-42. PubMed ID: 20712603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme.
    Yu M; Van Brunt K; Varnado OJ; Boye KS
    Diabetes Obes Metab; 2016 Apr; 18(4):419-24. PubMed ID: 26691396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disutility of injectable therapies in obesity and type 2 diabetes mellitus: general population preferences in the UK, Canada, and China.
    McEwan P; Baker-Knight J; Ásbjörnsdóttir B; Yi Y; Fox A; Wyn R
    Eur J Health Econ; 2023 Mar; 24(2):187-196. PubMed ID: 35526173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimation of the relationship between body mass index and EQ-5D health utilities in individuals with type 2 diabetes: evidence from the population-based KORA studies.
    Hunger M; Schunk M; Meisinger C; Peters A; Holle R
    J Diabetes Complications; 2012; 26(5):413-8. PubMed ID: 22699110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.